Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab Rezetecan or Irinotecan Liposome (II) Plus Anlotinib in HER2-Aberrant Sarcomas and Solid Tumors
ChiCTR2600127270Phase 2Not yet recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Jun 2026
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of trastuzumab rezetecan, irinotecan liposome and anlotinib in small round cell sarcoma (SRBCT) and Nonhematologic neoplasms (4 cohorts), sponsored by Zhejiang Cancer Hospital. Primary endpoint: Objective response rate. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
trastuzumab rezetecanirinotecan liposomeanlotinib
03
Conditions
small round cell sarcoma (SRBCT)Nonhematologic neoplasms
Beyond the preview
Go deeper on ChiCTR2600127270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600127270.